
Cancers | Highly Cited Papers Related to Lung Cancer
Lung cancer stands as one of the most complex and life-threatening diseases globally, posing significant challenges in clinical practice. To showcase the latest breakthroughs in lung cancer research, Cancers (ISSN 2072-6694) has selected a collection of highly cited articles published in 2025 alongside popular Special Issues. Spanning diverse topics such as AI-driven liquid biopsy, advanced radiotherapy, novel targeted/immune therapies, surgical innovations, and spatial transcriptomics, these papers highlight new frontiers in precision oncology while tackling hurdles like drug resistance and tumor heterogeneity. We encourage readers to explore and download these exceptional works from the webpage. We trust these contributions will deliver profound insights and significantly support future advancements in lung cancer management.
The list of highly cited papers can be viewed below:
“Benefits from 18F-FDG PET-CT-Based Radiotherapy Planning in Stage III Non-Small-Cell Lung Cancer: A Prospective Single-Center Study”
by Admir Mulita, Pipitsa Valsamaki, Eleni Bekou, Stavros Anevlavis, Christos Nanos, Athanasios Zisimopoulos, Alexandra Giatromanolaki and Michael I. Koukourakis
Cancers 2025, 17(12), 1969; https://doi.org/10.3390/cancers17121969
“Artificial Intelligence-Enhanced Liquid Biopsy and Radiomics in Early-Stage Lung Cancer Detection: A Precision Oncology Paradigm”
by Swathi Priya Cherukuri, Anmolpreet Kaur, Bipasha Goyal, Hanisha Reddy Kukunoor, Areesh Fatima Sahito, Pratyush Sachdeva, Gayathri Yerrapragada, Poonguzhali Elangovan, Mohammed Naveed Shariff, Thangeswaran Natarajan et al.
Cancers 2025, 17(19), 3165; https://doi.org/10.3390/cancers17193165
“Optimizing Osimertinib for NSCLC: Targeting Resistance and Exploring Combination Therapeutics”
by Yan-You Liao, Chia-Luen Tsai and Hsiang-Po Huang
Cancers 2025, 17(3), 459; https://doi.org/10.3390/cancers17030459
“Targeting Immune Checkpoint Inhibitors for Non-Small-Cell Lung Cancer: Beyond PD-1/PD-L1 Monoclonal Antibodies”
by Nicolas Roussot, Courèche Kaderbhai and François Ghiringhelli
Cancers 2025, 17(5), 906; https://doi.org/10.3390/cancers17050906
“Recent Advances in the Clinical Translation of Small-Cell Lung Cancer Therapeutics”
by Subhadeep Das and Shayak Samaddar
Cancers 2025, 17(2), 255; https://doi.org/10.3390/cancers17020255
“Emerging Targeted Therapies in Non-Small-Cell Lung Cancer (NSCLC)”
by Syeda A. Mina, Mohamed Shanshal, Konstantinos Leventakos and Kaushal Parikh
Cancers 2025, 17(3), 353; https://doi.org/10.3390/cancers17030353
“Surgical Techniques for Non-Small-Cell Lung Cancer After Neoadjuvant Chemo-Immunotherapy: State of Art and Review of the Literature”
by Beatrice Trabalza Marinucci, Massimiliano Mancini, Alessandra Siciliani, Fabiana Messa, Giorgia Piccioni, Antonio D’Andrilli, Giulio Maurizi, Anna Maria Ciccone, Cecilia Menna, Camilla Vanni et al.
Cancers 2025, 17(4), 638; https://doi.org/10.3390/cancers17040638
“Tumor Heterogeneity and the Immune Response in Non-Small Cell Lung Cancer: Emerging Insights and Implications for Immunotherapy”
by Michael S. Oh, Jensen Abascal, Austin K. Rennels, Ramin Salehi-Rad, Steven M. Dubinett and Bin Liu
Cancers 2025, 17(6), 1027; https://doi.org/10.3390/cancers17061027
“Spatial Transcriptomics in Lung Cancer and Pulmonary Diseases: A Comprehensive Review”
by Da Hyun Kang, Yoonjoo Kim, Ji Hyeon Lee, Hyeong Seok Kang and Chaeuk Chung
Cancers 2025, 17(12), 1912; https://doi.org/10.3390/cancers17121912
“Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor (EGFR) Common Mutations: New Strategies”
by Brigida Stanzione, Alessandro Del Conte, Elisa Bertoli, Elisa De Carlo, Martina Bortolot, Sara Torresan, Michele Spina and Alessandra Bearz
Cancers 2025, 17(9), 1515; https://doi.org/10.3390/cancers17091515
The list of relevant Special Issues can be viewed below:
“Clinical Update on Lung Cancer: Current Strategies and Outcome”
Guest Editor: Dr. Antonio D'Andrilli
Submission deadline: 15 March 2027
“Advances in Lung Cancer Treatment Strategies”
Guest Editors: Dr. Alessandro Gonfiotti and Dr. Alice Ravasin
Submission deadline: 15 April 2027

You are welcome to submit relevant papers to Cancers.
Cancers Editorial Office